NO331083B1 - Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati - Google Patents

Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati

Info

Publication number
NO331083B1
NO331083B1 NO20033228A NO20033228A NO331083B1 NO 331083 B1 NO331083 B1 NO 331083B1 NO 20033228 A NO20033228 A NO 20033228A NO 20033228 A NO20033228 A NO 20033228A NO 331083 B1 NO331083 B1 NO 331083B1
Authority
NO
Norway
Prior art keywords
inhibitor
expression vector
cardiomyopathy
inducing
enhancing
Prior art date
Application number
NO20033228A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033228L (no
NO20033228D0 (no
Inventor
Charles Dinarello
Yolande Chvatchko
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20033228D0 publication Critical patent/NO20033228D0/no
Publication of NO20033228L publication Critical patent/NO20033228L/no
Publication of NO331083B1 publication Critical patent/NO331083B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20033228A 2001-01-29 2003-07-16 Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati NO331083B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (3)

Publication Number Publication Date
NO20033228D0 NO20033228D0 (no) 2003-07-16
NO20033228L NO20033228L (no) 2003-09-26
NO331083B1 true NO331083B1 (no) 2011-10-03

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033228A NO331083B1 (no) 2001-01-29 2003-07-16 Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati

Country Status (32)

Country Link
US (1) US20040234523A1 (sr)
EP (1) EP1355668B1 (sr)
JP (2) JP4860897B2 (sr)
KR (1) KR100857376B1 (sr)
CN (1) CN1326562C (sr)
AR (1) AR032422A1 (sr)
AT (1) ATE380558T1 (sr)
BG (1) BG66483B1 (sr)
BR (1) BR0206819A (sr)
CA (1) CA2435466C (sr)
CY (1) CY1107203T1 (sr)
CZ (1) CZ305653B6 (sr)
DE (1) DE60224004T2 (sr)
DK (1) DK1355668T3 (sr)
EA (2) EA010180B1 (sr)
EE (1) EE05534B1 (sr)
ES (1) ES2295332T3 (sr)
HK (1) HK1062810A1 (sr)
HR (1) HRP20030609A2 (sr)
HU (1) HU229164B1 (sr)
IL (2) IL157024A0 (sr)
ME (1) ME00549B (sr)
MX (1) MXPA03006776A (sr)
NO (1) NO331083B1 (sr)
PL (1) PL213568B1 (sr)
PT (1) PT1355668E (sr)
RS (1) RS51125B (sr)
SI (1) SI1355668T1 (sr)
SK (1) SK287620B6 (sr)
UA (1) UA80676C2 (sr)
WO (1) WO2002060479A1 (sr)
ZA (1) ZA200305439B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
EP1331943A4 (en) 2000-10-11 2005-01-26 Viron Therapeutics Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
PL1622939T3 (pl) 2003-05-13 2012-08-31 Merck Serono Sa Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
CA2610804C (en) 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein
US8034573B2 (en) * 2007-11-05 2011-10-11 Kci Licensing Inc. Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
MY194040A (en) * 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ES2255112T3 (es) * 1996-09-12 2006-06-16 Idun Pharmaceuticals, Inc. Inhibicion de apoptosis usando inhibidores de la familia de la enzima convertidora de interleucina 1-beta (ice)/ced-3.
CA2274250A1 (en) * 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1.beta. converting enzyme
JP2002504091A (ja) * 1997-03-18 2002-02-05 ベーアーエスエフ アクツィエンゲゼルシャフト コルチコステロイドに対する応答性を調整するための方法及び組成物
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
JP2002539183A (ja) * 1999-03-16 2002-11-19 サイトビア インコーポレイテッド 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用
DE60035037T2 (de) * 1999-04-09 2008-01-31 Cytovia, Inc., San Diego Caspase inhibitoren und ihre verwendung
WO2001003719A2 (en) * 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2001085201A2 (en) * 2000-05-05 2001-11-15 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
IL157024A (en) 2014-02-27
IL157024A0 (en) 2004-02-08
EA200501549A1 (ru) 2006-04-28
ATE380558T1 (de) 2007-12-15
BG66483B1 (bg) 2015-03-31
HUP0303306A3 (en) 2005-12-28
EP1355668B1 (en) 2007-12-12
CN1326562C (zh) 2007-07-18
YU57803A (sh) 2006-05-25
NO20033228L (no) 2003-09-26
PL366802A1 (en) 2005-02-07
ES2295332T3 (es) 2008-04-16
WO2002060479A1 (en) 2002-08-08
HRP20030609A2 (en) 2005-06-30
HK1062810A1 (en) 2004-11-26
MXPA03006776A (es) 2003-10-24
HU229164B1 (en) 2013-09-30
ME00549B (me) 2011-10-10
EP1355668A1 (en) 2003-10-29
CA2435466C (en) 2012-04-03
CN1499982A (zh) 2004-05-26
CA2435466A1 (en) 2002-08-08
SK10892003A3 (sk) 2004-02-03
ZA200305439B (en) 2004-07-15
EA200300844A1 (ru) 2003-12-25
DE60224004D1 (de) 2008-01-24
BG108128A (bg) 2004-11-30
BR0206819A (pt) 2004-02-03
KR100857376B1 (ko) 2008-09-05
RS51125B (sr) 2010-10-31
PT1355668E (pt) 2008-01-04
UA80676C2 (en) 2007-10-25
CY1107203T1 (el) 2012-11-21
HUP0303306A2 (hu) 2004-01-28
US20040234523A1 (en) 2004-11-25
EE05534B1 (et) 2012-04-16
DE60224004T2 (de) 2009-07-23
AR032422A1 (es) 2003-11-05
JP4860897B2 (ja) 2012-01-25
NO20033228D0 (no) 2003-07-16
PL213568B1 (pl) 2013-03-29
JP2009102354A (ja) 2009-05-14
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
EE200300328A (et) 2003-10-15
DK1355668T3 (da) 2008-05-05
SI1355668T1 (sl) 2008-06-30
CZ305653B6 (cs) 2016-01-27
EA006767B1 (ru) 2006-04-28
JP2004522748A (ja) 2004-07-29
EA010180B1 (ru) 2008-06-30
CZ20032335A3 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
NO20062508L (no) Administrering av levodopa og karbidopa
DK1590047T3 (da) Sammensætning, som omfatter lactobacillus eller bifidobacterium, og anvendelse deraf
DK1373191T3 (da) Acylerede indanylaminer og deres anvendelse som lægemidler
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
IS7079A (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
DK1516053T3 (da) Xylanaser, nucleinsyrer, som koder herfor, og fremgangsmåder til at fremstille og benytte disse
NO331083B1 (no) Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20042478L (no) Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
NO20044665L (no) Renzoksazin-derivater som 5-HT6-modulatorer og anvendelser derav
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20053588D0 (no) Acylaminotiazol-derivater, fremstilling og anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer.
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
DK1353912T3 (da) 2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired